KR860700044A - Aids 관련의 레트로 비루스 (htlv-ⅲ)의 연속생산의 방법 및 그를 위한 셀라인 - Google Patents

Aids 관련의 레트로 비루스 (htlv-ⅲ)의 연속생산의 방법 및 그를 위한 셀라인

Info

Publication number
KR860700044A
KR860700044A KR1019850700403A KR850700403A KR860700044A KR 860700044 A KR860700044 A KR 860700044A KR 1019850700403 A KR1019850700403 A KR 1019850700403A KR 850700403 A KR850700403 A KR 850700403A KR 860700044 A KR860700044 A KR 860700044A
Authority
KR
South Korea
Prior art keywords
cell
htlv
target
cells
iii
Prior art date
Application number
KR1019850700403A
Other languages
English (en)
Other versions
KR910003916B1 (ko
Inventor
로버트 시. 갈로 (외 1)
Original Assignee
다비드 티. 모우리(미국 상무성연방기술이용센터부소장)
미합중국 대표 미국 상무성
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/602,946 external-priority patent/US4647773A/en
Application filed by 다비드 티. 모우리(미국 상무성연방기술이용센터부소장), 미합중국 대표 미국 상무성 filed Critical 다비드 티. 모우리(미국 상무성연방기술이용센터부소장)
Publication of KR860700044A publication Critical patent/KR860700044A/ko
Application granted granted Critical
Publication of KR910003916B1 publication Critical patent/KR910003916B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

AIDS 관련의 레트로 비루스 (HTLV-Ⅲ)의 연속생산의 방법 및 그를 위한 셀라인
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 표적 T-세포를 HTLV-Ⅲ 비루스로 감염시키며 HTLV-Ⅲ 의 전형적인 세표병리적 작용을 약화시킨후 그 표적 T-세포의 영속 생장성을 보존시키는 것을 특징으로 하는 HTLV-Ⅲ 비루스의 생산방법.
  2. 제1항에 있어서, 그 표적 T-세포가 표적 OKT4+ T-세포인 것을 특징으로하는 방법.
  3. 제1항에 있어서, 그 표적 T-세포가 HT 클론인 것을 특징으로하는 방법.
  4. 제3항에 있어서, HT 클론이 H4 클론인 것을 특징으로하는 방법.
  5. 제3항에 있어서, HT 클론이 H9 클론인 것을 특징으로하는 방법.
  6. 제1항에 있어서, HTLV-Ⅲ 비루스가 세포 병리작용을 나타내며 비-전환된 인체 T 임파추향성 레트로비루스의 변형주를 포함하는 것을 특징으로 하는 방법.
  7. 제1 내지 6항중 어느 한항에 있어서, 표적 T-세포가 종양 이수배수체 T-세포인 것을 특징으로 하는 방법.
  8. 제7항에 있어서, 표적 T-세포가 임파구 백혈병으로부터 유래된 T-셀라인 것을 특징으로 하는 방법.
  9. 제8항에 있어서, T-셀라인의 OKT3+(62%), OKT4+(39%), OKT8-의 숙성형 T-세포 표현형을 가지는 것을 특징으로하는 방법.
  10. 제2항에 있어서, 표적 T-세포가 Molt 3, CEM, Ti 7.4와 HUT 78 세포로부터 선택되는 것을 특징으로하는 방법.
  11. 제8항에 있어서, 그 셀라인이 HTLV-Ⅲ를 연속적으로 대규모로 생산할수 있는 것을 특징으로 하는 방법.
  12. 제1,6,9와 10항중 어느 한 항에 있어서, 표적 T-세포가 HTLV-Ⅲ 비루스와 함께 공배양됨으로써 감염되는 것을 특징으로하는 방법.
  13. 제7항에 있어서, 그 표적 T-세포가 HTLV-Ⅲ 비루스와의 공배양에 의해 감염되는 것을 특징으로 하는 방법.
  14. 제8항에 있어서, 그 표적 T-세포가 HTLV-Ⅲ 비루스와의 공배양에 의해 감염되는 것을 특징으로 하는 방법.
  15. 제1,6,9와 10항중 어느 한항에 있어서, 그 표적 T-세포가 세포-유리감염에 의해 HTLV-Ⅲ 비루스로 감염되는 것을 특징으로하는 방법.
  16. 제7항에 있어서, 그 표적 T-세포가 세포-유리 감염에 의해 HTLV-Ⅲ로 감염되는 것을 특징으로하는 방법.
  17. 제8항에 있어서, 그 표적 T-세포가 세포-유리 감염에 의해 HTLV-Ⅲ 비루스로 감염되는 것을 특징으로하는 방법.
  18. 제11항에 있어서, 그 표적 T-세포가 세포-유리 감염에 의해 HTLV-Ⅲ로 감염되는 것을 특징으로하는 방법.
  19. HTLV-Ⅲ 비루스로 감염된 T-세포를 함유하는 것을 특징으로하는 셀라인.
  20. 제19항에 있어서, 그 T-셀라인이 H9/HTLV-ⅢB(ATCC 기탁번호 CRL 8543)인 것을 특징으로하는 T-셀라인.
  21. 제19항에 있어서, 그 T-세포가 OKT4+허용성 세포인 것을 특징으로하는 T-셀라인
  22. 제21항에 있어서, 그 OKT4+허용성 세포가 Molt 3, CEM, Ti 7.4와 HUT 78 세포중 적어도 하나를 함유하는 것을 특징으로 하는 셀라인.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850700403A 1984-04-23 1985-04-23 후천성 면역 결핍증후군(aids)과 관계가 있는 레트로 비루스(htlv-iii)의 연속적인 생산을 위한 방법과 셀라인 KR910003916B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US602946 1984-04-23
US06/602,946 US4647773A (en) 1984-04-23 1984-04-23 Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
US602,946 1984-04-23
US06/643,729 US4652599A (en) 1984-04-23 1984-08-24 Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS using permissive cells
US643,729 1984-08-24
US643729 1984-08-24
PCT/US1985/000720 WO1985004897A1 (en) 1984-04-23 1985-04-23 Method and cell line for continuous production of retroviruses (htlv-iii) related to aids

Publications (2)

Publication Number Publication Date
KR860700044A true KR860700044A (ko) 1986-01-31
KR910003916B1 KR910003916B1 (ko) 1991-06-15

Family

ID=27084286

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850700403A KR910003916B1 (ko) 1984-04-23 1985-04-23 후천성 면역 결핍증후군(aids)과 관계가 있는 레트로 비루스(htlv-iii)의 연속적인 생산을 위한 방법과 셀라인

Country Status (13)

Country Link
US (1) US4652599A (ko)
EP (1) EP0179871B1 (ko)
JP (1) JP2686892B2 (ko)
KR (1) KR910003916B1 (ko)
AU (1) AU560887B2 (ko)
CA (1) CA1266243A (ko)
DE (1) DE3583484D1 (ko)
GR (1) GR850975B (ko)
IE (1) IE58320B1 (ko)
IL (1) IL74994A (ko)
NZ (1) NZ211859A (ko)
SG (1) SG34892G (ko)
WO (1) WO1985004897A1 (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
IE58321B1 (en) * 1984-04-23 1993-09-08 Us Health Isolation of proteins of HTLV-III, serological detection of antibodies to HTLV-III in sera of patients with aids and pre-aids conditions, and detection of HTLV-III infection bi/immuno-assays using HTLV-III infection by immuno-assays using HTLV-III and its proteins
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9309574B1 (en) 1984-08-22 2016-04-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Molecular cloning of HIV-1 from immortalized cell lines
US7393949B1 (en) 1987-12-24 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
US7273695B1 (en) 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
GB8500918D0 (en) * 1985-01-15 1985-02-20 Cancer Res Inst Viral isolates
DE3690028T (ko) * 1985-01-15 1987-03-12
US5386022A (en) * 1985-03-28 1995-01-31 Hoffman-La Roche Inc. Primes and probes for the amplification and detection of aids associated nucleic acids
US5176995A (en) * 1985-03-28 1993-01-05 Hoffmann-La Roche Inc. Detection of viruses by amplification and hybridization
US5008182A (en) * 1986-01-10 1991-04-16 Cetus Corporation Detection of AIDS associated virus by polymerase chain reaction
JPS62115278A (ja) * 1985-09-13 1987-05-26 アンステイテユ・パストウ−ル ヒトクラス２組織適合抗原を欠く細胞系の利用方法
PT84182B (pt) * 1986-01-22 1989-09-14 Pasteur Institut Novo retrovirus susceptivel de provocar o sida, meios e processos para a sua deteccao "in vitro"
FR2594229B1 (fr) * 1986-02-13 1989-05-19 Pasteur Institut Nouveau retrovirus du type lav-ii susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
US6037165A (en) 1986-01-22 2000-03-14 Institut Pasteur Methods for the preparation of human immunodeficiency virus type 2 (HIV-2) and antigens encoped thereby
FR2596063B1 (fr) * 1986-03-18 1989-05-19 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
US5976785A (en) * 1986-01-22 1999-11-02 Institut Pasteur Competitive assays for determining the effectiveness of a human immunodeficiency virus type 2 (HIV-2) antiviral agent, employing peptides and proteins of HIV-2
FR2593190B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
US6514691B1 (en) * 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US5079342A (en) * 1986-01-22 1992-01-07 Institut Pasteur Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5364933A (en) 1986-03-03 1994-11-15 Institut Pasteur Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2)
US5580739A (en) 1986-01-22 1996-12-03 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2) and in vitro diagnostic methods and kits employing the peptides for the detection of HIV-2
US5830641A (en) * 1986-01-22 1998-11-03 Institut Pasteur In vitro diagnostic assays for the detection of HIV-1 or HIV-2 employing viral-specific antigens and antibodies
US5306614A (en) * 1986-01-22 1994-04-26 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2(HIV-2)
FR2593189B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
FR2597500B1 (fr) * 1986-03-24 1989-06-02 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
US4753873A (en) * 1986-02-03 1988-06-28 Cambridge Bioscience Corporation Peptides for the diagnosis of HTLV-III antibodies, their preparation and use
US6054565A (en) * 1986-03-03 2000-04-25 Institut Pasteur Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
US4752565A (en) * 1986-04-07 1988-06-21 The United States Of America As Represented By The Department Of Health And Human Services Cell line producing AIDS viral antigens without producing infectious virus particles
FR2599756A1 (fr) * 1986-06-10 1987-12-11 Pasteur Institut Mitogenes streptococciques specifiques des lymphocytes t4, leur application a la stimulation de la production de virus lav
EP0269520A3 (fr) * 1986-11-21 1988-08-24 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le sida, et ses constituants antigéniques et nucléiques
SE8605535L (sv) * 1986-12-22 1988-06-23 Birgitta Asjo Cellsystem, dess framstellning och anvendning
AU609447B2 (en) * 1987-02-19 1991-05-02 Nissin Shokuhin Kabushiki Kaisha Methods and materials for hiv detection and therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
JP2810179B2 (ja) * 1988-08-16 1998-10-15 アクゾ・エヌ・ヴエー 天然型ｈｉｖ ｇｐ１６０の製造方法

Also Published As

Publication number Publication date
AU560887B2 (en) 1987-04-16
AU4292685A (en) 1985-11-15
IE58320B1 (en) 1993-09-08
GR850975B (ko) 1985-11-25
JPH0670759A (ja) 1994-03-15
JP2686892B2 (ja) 1997-12-08
DE3583484D1 (de) 1991-08-22
EP0179871B1 (en) 1991-07-17
KR910003916B1 (ko) 1991-06-15
EP0179871A4 (en) 1986-09-04
IE851021L (en) 1985-10-23
US4652599A (en) 1987-03-24
EP0179871A1 (en) 1986-05-07
IL74994A0 (en) 1985-08-30
WO1985004897A1 (en) 1985-11-07
SG34892G (en) 1992-05-22
IL74994A (en) 1988-11-30
NZ211859A (en) 1989-05-29
CA1266243A (en) 1990-02-27

Similar Documents

Publication Publication Date Title
KR860700044A (ko) Aids 관련의 레트로 비루스 (htlv-ⅲ)의 연속생산의 방법 및 그를 위한 셀라인
AU3762889A (en) Hiv-3 retrovirus and its use
DE69331050T2 (de) Produktion virus-resistenter pflanzen durch einführung von nicht-translatierbarer viraler plus-strang-rna
DE3750506T2 (de) Copolymere aus Äthylen und 1,3-Butadien.
UA26439A (uk) Спосіб одержаhhя еластомерhих фтороваhих співполімерів
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
JPS56811A (en) Preparation of olefin polymer or copolymer
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
ATE88547T1 (de) Blasvorrichtung hoher festigkeit.
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
IT7920255A0 (it) Procedimento per produrre idrogeno e ossigeno, nonche' cella elettrolitica per attuare tale procedimento.
DE69332911D1 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
NO168216C (no) Fremgangsmaate til opprettelse av mellomrommet mellom tilstoetende tegn i et system for aa danne tekstlinjer
CA2130360A1 (en) Sulfonic Acid Derivatives in the Treatment of Viral Diseases
FR2415686A1 (fr) Emulsion d'empesage des tissus
ES468528A1 (es) Perfeccionamientos introducidos en las placas de compensa- cion para prensas vulcanizadoras o similares.
GB1156486A (en) Ketonic Flavouring Agents
BR9709524A (pt) Anticorpos contra um complexo de cd4 e um domìnio receptor de quimiocina e seu uso contra infecções de hiv
MX9700414A (es) Agentes antivirales de difluoroestatona.
FI102684B1 (fi) Menetelmä luontaisen HIV-gp160:n tuottamiseksi
DK0673422T3 (da) Celler, der er modificeret med hensyn til katabolismen af betain, fremstilling og anvendelser, navnlig til produktion af metabolitter eller enzymer
ES8603522A1 (es) Un procedimiento de fabricacion de copolimeros en bloques
Menna-Barreto et al. Human T-cell lymphotropic virus type II in Guarani Indians, Southern Brazil
Pal et al. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A
IKUTA et al. Amplification of human immunodeficiency virus production from a virus-producing cell line in culture at high cell density

Legal Events

Date Code Title Description
A201 Request for examination
E601 Decision to refuse application
E902 Notification of reason for refusal
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

Free format text: TRIAL NUMBER: 1989201001342; APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
O035 Opposition [patent]: request for opposition
E701 Decision to grant or registration of patent right
O073 Decision to grant registration after opposition [patent]: decision to grant registration
E601 Decision to refuse application
O063 Decision on refusal after opposition [patent]: decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

Free format text: TRIAL NUMBER: 1994201002430; APPEAL AGAINST DECISION TO DECLINE REFUSAL

E701 Decision to grant or registration of patent right
O073 Decision to grant registration after opposition [patent]: decision to grant registration
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040609

Year of fee payment: 14

EXPY Expiration of term